A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Key Inclusion Criteria:

• Is a male or female ≥18 years of age;

• Has a diagnosis of Type 1 or Type 2 diabetes, according to the American DiabetesAssociation criteria;

• Has a current diagnosis of diabetic gastroparesis defined by the following:

1. Persistent gastrointestinal symptoms that in the opinion of the Investigatorare consistent with gastroparesis within 6 months prior to Screening; AND

2. Documented delayed gastric emptying as determined by gastric emptying breathtest (GEBT), scintigraphy, or manometry.

• Body mass index (BMI) between 18 and 49 kg/m2, inclusive;

• Glycosylated hemoglobin (HbA1c) level <10% at Screening;

• If receiving treatment with GLP-1RA, may be considered for the study if all of thefollowing criteria are satisfied:

1. The GLP-1 RA has been prescribed for the management of diabetes and notspecifically for weight loss/weight management;

2. Has been on a stable dose of GLP-1RA for a minimum of 3 months before Screeningand is anticipated to sustain the same dose during GEBT and throughout thestudy;

3. Is tolerating the GLP-1RA well based on Investigator's judgment;

4. None of the study-qualifying signs/symptoms of gastroparesis are solelyattributable to the use of GLP-1RA; and

5. The symptoms of gastroparesis preceded the initiation of GLP-1RA therapy.

• Willing to washout from ongoing treatment for gastroparesis.

Key Exclusion Criteria:

• Has known cause of gastroparesis other than diabetes (eg, idiopathic gastroparesisand/or gastroparesis attributed to surgery, viral illness, cancer, scleroderma, orother neurologic disorder);

• Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesisand/or diabetic ketoacidosis and/or malnutrition;

• History or evidence of clinically significant arrhythmia;

• History of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy,fundoplication, gastrectomy, vagotomy, or bariatric surgery;

• Currently receiving parenteral feeding or presence of a nasogastric or other enteraltube for feeding or decompression;

• Pyloric injection of botulinum toxin within 6 months of Screening;

• Positive test for drugs of abuse;

• Has a known allergy to eggs or spirulina;

• Females who are pregnant, breastfeeding, or planning to become pregnant orbreastfeed during the study.